RANSFORMING growth factor-␤ is a multifunctional polypeptide implicated in the regulation of various cellular processes including growth, differentiation, apoptosis, adhesion, and motility. Transforming growth factor-␤ binds to two different types of serine/threonine kinase receptors, Type I and Type II. 28 The Type I receptor is activated by the Type II receptor on ligand binding and mediates specific intracellular signals (Fig. 1) . The activated Type I receptor then causes phosphorylation and activation of downstream signaling components including Smad2 and Smad3. After phosphorylation, Smad2 and Smad3 form heteromeric complexes with Smad4 and then migrate from the cytoplasm into the nucleus. 30 Nuclear Smad complexes bind to transcriptional coactivators or corepressors and regulate transcription of target genes.
novel gene). 47 The Ski gene is named for the SloanKettering Institute, where it was identified in the early 1980s as the culprit gene in a virus that causes tumors in chickens. 47 The sequence of Sno, found a few years later, is very similar to the human version of Ski. 34 Four Sno complementary DNAs, representing alternatively spliced forms, have been found in humans, including SnoN, 34 SnoA, 34 SnoI, 38 and SnoN2. 39 Both Ski and Sno are oncoproteins that, when overexpressed induce oncogenic transformation of chicken and quail embryo fibroblasts. 5 Both Ski and Sno also repress the antiproliferative effects of TGF␤. 1, 44 The SnoN protein is degraded by the Smad3 protein and then its expression is induced through a TGF␤ signaling cascade. 44, 46 It has been suggested that SnoN participates in the negative feedback control of TGF␤ signaling. 44 Transforming growth factor-␤ inhibits proliferation of various cell types by inhibiting the activity of CDKs; this leads to the arrest of the cell cycle in the early G 1 phase. 2, 41 The mechanism of action of TGF␤ in modulating the activity of CDKs involves the regulation of the CDK inhibitors p15Ink4B, p21Cip1, and p27Kip1. 7, 13, 41 Transcriptional induction of the genes for the two CDK inhibitors, p15 and p21, may partially determine the antiproliferating action of TGF␤. 17 Transforming growth factor-␤ also regulates the expression of cyclin D1 25, 26 and CDK4. 9 In our previous studies we found that malignant glioma cells secrete TGF␤, 21, 32 that thrombospondin-1 secreted by glioma cells participates in the activation of latent TGF␤, 43 and that malignant glioma cells are refractory to TGF␤ growth inhibition, despite the fact that they express TGF␤ receptors. 19 The mechanism underlying this effect, however, remains poorly understood.
In the present study we further investigated the mechanism of loss of sensitivity to TGF␤-mediated growth inhibition in malignant glioma cells by examining the expression of the downstream components of the TGF␤ receptor, including Smad2, Smad3, Smad4, and Smad7, and the effect of TGF␤ 1 treatment on the phosphorylation of Smad2 and nuclear translocation of Smad2 and Smad3. The expression of the transcriptional corepressor proteins SnoN and Ski, and the effect of TGF␤ 1 treatment on the expression of the SnoN protein and the cell cycle regulators p21, p15, CDK4, and cyclin D1 were also examined. Ten human malignant GBM cell lines (T98G, U251, A172,  KG1C, TM2, YMG1, YMG2, YMG3, YMG4, and lial cell line (Mv1Lu) were maintained in RPMI-1640 medium, which had been supplemented with 10% fetal bovine serum and 100 g/ml kanamycin. The T98G, U251, A172, KG1C, and A549 cell lines were obtained from the Health Science Research Resources Bank, (Tokyo, Japan). The T98G, U251, A172, and KG1C cell lines have been widely used and are characterized by the expression of GFAP and/or S100 protein. The TM2 cell line, which expresses GFAP and S100, was donated by Dr. Masaki Kurimoto (Department of Neurosurgery, Toyama Medical and Pharmaceutical University, Toyama, Japan). The YMG1, YMG2, YMG3, YMG4, and YMG5 cell lines were derived from GBMs or anaplastic astrocytomas and established in our laboratory. 48 All five of these cell lines express S100 and three of them (specifically, YMG1, YMG3, and YMG5) express GFAP. The YMG3 and YMG4 cell lines express the p15 and p16 proteins, and the other three do not. A sample of a normal human astrocyte was obtained from Cambrex Bio Science Walkersville, Inc., (Walkersville, MD) and cultured according to the manufacturer's protocol. The Jurkat cell line (human T-cell leukemia) was donated by one of the authors (A.N.) and its cell lysate was used as a positive control for the Smad4 protein. The sensitivity of Mv1Lu and A549 cells to TGF␤-mediated growth inhibition was evaluated in a previous study. 32 
Materials and Methods

Cell Culture and Surgical Specimens
Antibodies and Reagents
The primary antibodies used in this study were rabbit antiSmad2/3 antibody (Upstate Biotechnology, Inc., Lake Placid, NY); rabbit anti-phospho-Smad2 (Ser465/467) antibody (Cell Signaling Technology, Inc., Beverly, MA); mouse anti-Smad4 antibody (BD Biosciences, San Diego, CA); goat anti-Smad7 antibody (Abcam Ltd., Cambridge, United Kingdom); rabbit anti-Ski antibody, rabbit anti-Sno antibody, mouse anti-p21Cip1 antibody, and mouse antip15 INK4B antibody (Upstate Biotechnology, Inc.); rabbit anti-cyclin D1 antibody, rabbit anti-CDK4 antibody, and rabbit anti-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-heat shock protein 70 antibody (Transduction Laboratories, Lexington, KY); and mouse anti-PCNA antibody (BD Biosciences). The secondary antibodies were alkaline phosphatase-conjugated swine anti-rabbit and rabbit anti-mouse antibodies (DakoCytomation, Carpinteria, CA) and alkaline phosphatase-conjugated rabbit anti-goat antibody (Chemicon, Inc., Temecula, CA). Horseradish peroxidaseconjugated goat anti-rabbit antibody and LumiGLO Reagent were obtained from Cell Signaling Technology, Inc. Recombinant human TGF␤ 1 was obtained from PeproTech (London, United Kingdom). Hela cell lysate was obtained from Upstate Biotechnology, Inc., and used as a positive control for the SnoN and Ski proteins in a Western blot analysis. The HepG2 cell lysate was obtained from Abcam Ltd. and used as a positive control for Smad7.
Growth Inhibition Assay Performed Using TGF␤ 1
The effect of TGF␤ 1 on the growth of the Mv1Lu and A549 cell lines and the 10 malignant glioma cell lines was examined in a manner described previously. 32 Briefly, 100-l aliquots of recombinant TGF␤ 1 (5 ng/ml) were placed in a 96-well plate in triplicate experiments and serial twofold dilutions were made in the plate. Fiftymicroliter aliquots of each cell suspension (2000 cells) were added to each well. After incubation for 72 hours at 37˚C in 5% CO 2 , the medium was decanted, and the cells were stained for 5 minutes with 0.5% crystal violet dissolved in 20% methanol. After washing, the dye was eluted with 50% ethanol, and the absorbance at 570 nm was determined with the aid of a spectrophotometer. The value of the optical density correlates with the number of cells in a well. 32 
Treatment of Cells With Recombinant TGF␤ 1
Malignant glioma cells, A549 cells, and normal human astrocytes were cultured in 6-or 9-cm dishes until they were subconfluent. The cells were incubated for 30 minutes with TGF␤ 1 (5 ng/ml) for an analysis of Smad2 phosphorylation and SnoN expression and for 12 hours with TGF␤ 1 (5 ng/ml) for an analysis of the effect of TGF␤ 1 on the expression of SnoN, p21, p15, cyclin D1, and CDK4 proteins. In preliminary studies, p21 protein expression reached the maximal level at least 12 hours after TGF␤ 1 treatment (data not shown). The cells were washed twice with phosphate-buffered saline, and cell lysates were prepared by lysing cells in a RIPA lysis buffer (Upstate Biotechnology, Inc.).
Nuclear/Cytosol Fractionation
The 10 malignant glioma cell lines and the A549 cell line were treated with TGF␤ 1 (5 ng/ml) for 60 minutes to examine the translocation of Smad2 and Smad3 proteins from the cytoplasm to the nuclear compartment and the expression of SnoN protein. Cell lysates were prepared as described earlier. The cell lysates were separated into nuclear and cytoplasmic fractions by using the Nuclear/Cytosol Fractionation Kit (BioVision, Mountain View, CA) according to the manufacturer's protocol. The fractionated samples were subjected to a Western blot analysis to detect Smad2, Smad3, and SnoN. The fractionated samples from untreated malignant glioma and A549 cells were also analyzed for Smad7. The efficacy of the fractionation was examined using antiactin and anti-heat shock protein 70 antibodies as internal controls in the Western blot analysis.
Western Blot Analysis
The cell lysates from each sample were separated on 6, 10, or 16% sodium dodecyl sulfate polyacrylamide gels (TEFCO, Tokyo, Japan) and electroblotted on a polyvinylidene difluoride membrane (Millipore, Bedford, MA). The membranes were treated with 5% nonfat dry milk or 5% bovine serum albumin in Tris-buffered saline with 0.1% Tween-20 for 1 hour at room temperature or overnight at 4˚C. After the membranes had been washed, they were incubated with primary antibodies for 1 hour at room temperature or overnight at 4˚C. The membranes were again washed and incubated with secondary antibodies for 1 hour at room temperature. Following this, each membrane was incubated with CDP-Star substrate (Roche, Mannheim, Germany) to develop the signal. The immunoblot signals were visualized by chemiluminescence and recorded with the aid of an image analyzer (LAS1000 Lumino Image Analyzer; Fuji Photo Film, Tokyo, Japan). For the horseradish peroxidase-conjugated secondary antibody, LumiGLO agent (Cell Signaling, Technology, Inc.) was used to develop the signal, which was also visualized by chemiluminescence. As internal controls for protein content from whole cell lysate and nuclear protein, the lysates were analyzed using antiactin and anti-PCNA antibodies, respectively.
Results
Effect of TGF␤ 1 on the Growth of Malignant Glioma Cells
The growth of the Mv1Lu and A549 cell lines was inhibited by TGF␤ 1 in a dose-dependent manner (Fig. 2) . The A549 cell line demonstrated some resistance, even to high doses (5 ng/ml) of TGF␤ 1 compared with the Mv1Lu cell line. Six of the 10 malignant glioma cell lines displayed resistance to high doses (5 ng/ml) of TGF␤ 1 , whereas three cell lines (U251, A172, and YMG3) showed weak sensitivity and one cell line (YMG2) demonstrated moderate sensitivity (Fig. 3) .
Expression of Smad Proteins
The expression of the Smad2 and Smad3 proteins was variable and low in malignant glioma cell lines compared with the TGF␤-sensitive A549 cell line and normal astrocytes (Fig. 4) . Six (T98G, U251, YMG1, YMG2, YMG3, and YMG5) of the 10 glioma cell lines demonstrated weaker expression of Smad2 than the A549 cell line. Nine glioma cell lines displayed lower expression of Smad3 than the A549 cell line, and six of these cell lines showed very low levels of Smad3. Only the YMG2 cell line exhibited a level of Smad3 comparable to those of the A549 cell line and normal astrocytes. In four glioma cell lines (T98G, U251, KG1C, and YMG2), the expression of the Smad4 protein was lower than that in the A549 cell line and was comparable to the expression observed in the other six cell lines (Fig. 4) . The expression of the Smad7 protein in glioma cell lines was comparable to the expression of that protein in A549 cell lines and normal astrocytes (Fig. 4) .
Cellular Localization of Smad7
Western blotting was used to analyze the cytoplasmic and nuclear fractions of glioma cell lysates for Smad7, which prevents signaling by inhibiting the phosphorylation of Smad2 and Smad3, because Smad7 is located in the nucleus in many types of cells 20 and in the cytoplasm in certain cells.
14 The Smad7 protein was mostly localized in the cytoplasm in the malignant glioma and A549 cell lines (Fig. 5) .
Effect of TGF␤ 1 on the Phosphorylation of Smad2
To examine whether malignant glioma cells have an ability to phosphorylate Smad2 by means of the TGF␤ receptor complex, we analyzed the phosphorylation of Smad2 after TGF␤ treatment. Only the KG1C cell line displayed a level of phosphorylated Smad2 that was comparable to that in normal astrocytes and A549 cell lines (Fig. 6) . The levels of phosphorylated Smad2 in the other cell lines were lower than levels observed in A549 cells and normal human astrocytes.
Effect of TGF␤ 1 on Translocation of Smad2 and Smad3 to the Nucleus
Phosphorylated Smad2 and Smad3 form heteromeric complexes with Smad4 and move from the cytoplasm to the nucleus. 30 The levels of Smad2 and Smad3 decreased in the cytoplasm and increased in the nucleus after TGF␤ 1 treatment in the TGF␤-sensitive A549 cell line (Fig. 6) . Only the YMG2 cell line displayed a comparable level of translocation of Smad2 and Smad3. Seven glioma cell lines (T98G, U251, A172, YMG1, YMG3, YMG4, and YMG5) exhibited small changes in Smad2 and Smad3 levels, and two glioma cell lines (KG1C and TM2) showed no changes. Interestingly, the KG1C and TM2 cell lines were completely resistant to TGF␤ 1 (Fig. 3) and exhibited very low levels of Smad3 protein (Fig. 4) . Although the KG1C cell line displayed a high level of Smad2 phosphorylation, no obvious translocation of Smad2 was observed from the cytoplasm to the nucleus.
Expression of the Transcriptional Corepressors Ski and SnoN
The SnoN and Ski proteins are transcriptional corepressors and negatively regulate the TGF␤ signaling pathway. 47 The anti-Sno antibody used in the present study recognizes a carboxyl terminus of SnoN (684 amino acids) and SnoN2 (638 amino acids), because the amino acid sequences of SnoN and SnoN2 are identical in the carboxyl terminus. In human tissues, SnoN2 is the less abundantly expressed isoform. 39 In Hela cell lysate used as a positive control for SnoN, a thick band (nearly 77 kD) would be SnoN and a thin band below the thick band would be SnoN2. The expression levels of the SnoN protein were high in all 10 malignant glioma cell lines, in the A549 cell line, and in normal astrocytes (Fig. 7) . The Ski protein was highly expressed in three glioma cell lines (TM2, YMG2, and YMG5) and weakly expressed in the other glioma cell lines, the A549 cell line, and normal astrocytes.
Effect of TGF␤ 1 Treatment on Expression of the SnoN Protein
We examined the effect of TGF␤ 1 treatment on the expression of the SnoN protein, because SnoN is rapidly degraded by the nuclear accumulation of Smad3. 44 After TGF␤ treatment, the SnoN protein reaches its lowest level by 30 minutes and an increase in SnoN messenger RNA occurs at 1 to 2 hours and lasts for 24 hours. 44 The levels of SnoN expression in whole-cell lysates did not change 30 minutes and 12 hours after TGF␤ 1 treatment in the A549 cell line and in normal astrocytes (Fig. 8A) . The levels of SnoN expression in the nuclear fraction did not decrease 60 minutes after TGF␤ 1 treatment in A549 cell line and in the 10 glioma cell lines (Fig. 8B) .
Effect of TGF␤ 1 on the Expression of the p21
Cip1
, Cyclin D1, and CDK4 Proteins
Expression of the p21 protein was low in seven of 10 glioma cell lines compared with expression of this protein in the A549 cell line and in normal astrocytes (Fig. 9) . Expression of the p21 protein increased after TGF␤ 1 treatment in the A549 cell line and in normal astrocytes. Among glioma cells, only the YMG2 cell line exhibited a slight increase in p21 expression; the other nine glioma cell lines showed no increase. This is in agreement with the finding that the YMG2 cell line showed moderate sensitivity to
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Abnormality in TGF␤ signaling pathway in glioma TGF␤-mediated growth inhibition (Fig. 3) . Expression of cyclin D1 increased after TGF␤ 1 treatment in the A549 cell line, but the expression of CDK4 was not affected (Fig. 9) . Expression of cyclin D1 and CDK4 proteins did not change in the malignant glioma cell lines or in normal astrocytes.
Effect of TGF␤ 1 on the Expression of p15
INK4B
In preliminary studies, 48 only three (TM2, YMG3, and YMG4) of the 10 malignant glioma cell lines expressed the p15 protein. The effect of TGF␤ 1 treatment on p15 expression was evaluated in these three cell lines, the A549 cell line, and normal astrocytes. The T98G and U251 cell lines, which did not express p15, were also used. The U251 cell line is known to lack p15 genes. 11 Treatment with TGF␤ 1 did not alter p15 expression in any of the glioma cell lines, the A549 cell line, or normal astrocytes (Fig. 10 ). The expression level of the p15 protein in normal astrocytes was lower than that in the TM2, YMG3, and YMG4 cell lines.
Discussion
The present study led to the identification of several abnormalities in the TGF␤ signaling pathway in the 10 glioma cell lines under investigation. First, the expression of both Smad2 and Smad3 proteins was variable and lower in glioma cell lines than in the A549 cell line and on normal astrocytes. Second, the level of phosphorylation of Smad2 after TGF␤ 1 treatment was lower in the malignant glioma cell lines than in the A549 cell line and in normal astrocytes. Third, translocation of Smad2 and Smad3 from the cytoplasm to the nucleus was impaired in the glioma cell lines. Fourth, the expression level of SnoN was not affected by TGF␤ 1 treatment in the glioma cell lines. Finally, induction of p21 and p15 proteins by TGF␤ 1 treatment was suppressed in the glioma cell lines.
Six of the 10 glioma cell lines expressed low levels of the Smad2 protein and nine expressed low levels of the Smad3 protein; none of the glioma cell lines displayed the levels of expression of Smad2 or Smad3 seen in the A549 cell line and normal astrocytes. Four of the glioma cell lines were observed to have low levels of Smad4 protein as well. These results agree with findings that messenger RNA expression of Smad2, Smad3, and Smad4 is decreased in GBM. 23 Phosphorylation of Smad2 and Smad3 is an initial event in the TGF␤ signaling cascade. Low levels of Smad2 and Smad3 proteins may result in a decrease in signal transmission via the TGF␤ receptor. Previous investigators have demonstrated the importance of Smad3 in mediating TGF␤ signaling. 29, 42 The Smad3 null mouse embryonic fibroblasts are partially resistant to the TGF␤-mediated antiproliferative effect. 6 Some gastric cancer cells display low to undetectable levels of Smad3. 12 Introduction of Smad3 into these human gastric cancer cells restored induction of p21 and p15 gene expression, and growth inhibition in response to TGF␤. These reports and the present results suggest that the expression of Smad3 is important in TGF␤ signaling in malignant glioma cells.
Overexpression of Smad7 has been reported to be present in some cancers. 4, 22, 24, 37 Enhanced expression of Smad7 may be one of the mechanisms of TGF␤ resistance in human gastric carcinomas 22 and pancreatic cancers. 24 In the present study, the glioma cells expressed levels of Smad7 that were comparable to those identified in the A549 cell line and in normal astrocytes. In many types of cells, Smad7 is located in the nucleus, 20 and in certain cells in the cytoplasm. 14 The present study revealed that the presence of Smad7 was mostly localized in the cytoplasm of glioma cells, suggesting the capability of Smad7 to inhibit phosphorylation of Smad2 and Smad3 by TGF␤ receptors.
The phosphorylated form of Smad2 is an indicator of cells responding to bioactive TGF␤ and nuclear translocation is a marker of activation of Smad2 and/or Smad3 in the TGF␤/Smad signaling cascade. 16, 36 In the present study we examined the expression of phosphorylated Smad2 after treatment with TGF␤ 1 . Nine of the 10 glioma cell lines expressed lower levels of phosphorylated Smad2 after TGF␤ 1 treatment than the A549 cell line or normal astrocytes. This finding is in agreement with the report that TGF␤ 1 induces phosphorylation of Smad2 in GBM cells. 40 Nevertheless, the present results also suggest impairment of levels of Smad2 phosphorylation by TGF␤ stimulation in glioma cells. We also found that translocation of Smad2 and Smad3 from the cytoplasm to the nucleus was impaired in nine glioma cell lines; the YMG2 cell line was the exception. Based on results showing that expression of Smad7 was not increased, but expression of Smad2 and Smad3 was low in glioma cell lines, we suggest that the relative abundance of Smad7 expression over that of Smad2 and Smad3 may result in impaired phosphorylation of Smad2 and thus in decreased translocation of Smad2 and Smad3. There were exceptions, however. The KG1C cell line displayed a comparable expression of phosphorylated Smad2 to that of the A549 cell line, but no obvious translocation of Smad2 to the nucleus. In contrast, YMG2 cells exhibited a low level of phosphorylated Smad2, but a similar level of translocation of Smad2 and Smad3 to the nucleus when compared to the A549 cell line. This difference between the two cell lines remains to be clarified.
Transforming growth factor-␤ upregulates the transcription of the CDK inhibitors p21 8 and p15, 13, 27 which inhibit CDK phosphorylation of the retinoblastoma protein and thus halt cell-cycle progression in the G 1 phase. 29 In the present study, the expression of p21 protein after TGF␤ 1 cell lines. Furthermore, the expression of p15 protein was not affected by TGF␤ treatment in glioma cell lines and in normal astrocytes. The transcriptional induction of p21 and p15 is mediated by Smad3 and Smad4 through Sp1 binding sites in the promoter of CDK inhibitor genes. 10, 35 The Smad3 protein is involved in the induction of p21 31 and p15 expression. 42 The present results showed that nine of the 10 glioma cell lines displayed low or very low levels of Smad3 protein. This suggests that the low levels of Smad3 failed to induce p21 and p15 expression in the malignant glioma cell lines. Interestingly, the glioma cell line (YMG2) whose level of Smad3 was comparable to that of the A549 cell line demonstrated some sensitivity to TGF␤-mediated growth inhibition. These observations suggest an important role of Smad3 in TGF␤ signaling.
The expression of cyclin D1 and CDK4 after TGF␤ treatment was also examined because TGF␤ regulates the expression of cyclin D1 25, 26 and CDK4. 9 Only the A549 cell line was found to have upregulation of cyclin D1 after TGF␤ treatment; the 10 glioma cell lines and the normal astrocytes showed no response. These results were similar to the response of p21 and p15 expression to TGF␤ 1 treatment. Transforming growth factor-␤ does not affect the level of cyclin D1 in Smad3-deficient colonocyte cells. 29 In the present study, however, the YMG2 cell line, which expresses Smad3, responded weakly to TGF␤ 1 , and showed a slight increase in p21 protein, did not show any change in the level of cyclin D1 protein after TGF␤ 1 treatment. These results suggest that the role of Smad3 in the induction of cyclin D1 after TGF␤ treatment is still unclear.
The expression of SnoN and Ski proteins has not been previously examined in malignant gliomas. In the present study, the levels of SnoN expression in glioma cell lines were comparable to those in the A549 cell line and in normal astrocytes, and overexpression of Ski was found in three glioma cell lines. Both Smad3 and Ski/Sno form a complex that specifically binds DNA in response to TGF␤ and overexpression of Ski/Sno proteins represses transcriptional activation by TGF␤. 45, 46 Interestingly, nuclear accumulation of Smad3 is important for degradation of the corepressor proteins Ski and SnoN. 44 The SnoN protein is rapidly degraded by the nuclear accumulation of Smad3, allowing the activation of TGF␤ target genes. In the present study, most glioma cell lines displayed low levels of Smad3 and a very small amount of Smad3 translocated to the nucleus after TGF␤ 1 treatment. This may be the reason why SnoN expression was not altered by TGF␤ 1 treatment in the glioma cell lines. The present results also suggest that the relative abundance of SnoN over Smad3 inhibited the activation of the TGF␤ target genes p21, p15, cyclin D1, and CDK4. 
Conclusions
In the present in vitro study, we found that glioma cell lines had multiple abnormalities in the TGF␤ signaling pathway from Smad2 phosphorylation by the TGF␤ receptor complex-which is the initial event of TGF␤ signaling-to expression of the TGF␤ target genes p21, p15, cyclin D1, and CDK4, which constitute the final events. These results suggest that the escape from TGF␤-mediated growth inhibition in malignant glioma cells is due to abnormalities in the TGF␤ signaling pathway. Given the present results, we need to investigate whether the same abnormalities in the TGF␤ signaling pathway exist in vivo in malignant glioma tissues. This approach may provide a potential therapeutic window to try to modulate the growth of malignant gliomas.
